CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kuros Biosciences AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kuros Biosciences AG
Wagistrasse 25
Phone: +41 447334747p:+41 447334747 SCHLIEREN, 8952  Switzerland Ticker: KURNKURN
Business Summary
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the research, development, and commercialization of biologic technologies for musculoskeletal care, with a focus on those supporting bone regeneration and bone growth. The Company's key product is MagnetOs, which is a synthetic bone graft technology available in multiple formats such as granules or putty. MagnetOs is designed to stimulate bone formation, including through mechanisms that engage the body’s immune response. The technology behind MagnetOs is associated with osteoimmunology, which involves immune-modulated bone healing. MagnetOs uses the proprietary NeedleGrip submicron surface technology, which supports bone growth by enhancing biological responses related to healing. It is indicated for use across the skeletal system and is positioned as a bone graft option for procedures involving various anatomical regions.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
7389 Business services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board of Directors ClemensVan Blitterswijk 68 6/14/2018 6/1/2017
Chief Executive Officer, Executive Director, Member of the Executive Board ChrisFair 55 4/17/2024 4/19/2021
Chief Financial Officer, Member of the Executive Board DanielGeiger 54 5/1/2023 5/1/2023
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Kuros Biosciences BV Professor Bonkhorstlaan 10 Bilthoven Netherlands

Business Names
Business Name
0RHR
CYTN
Cytos Biotechnology
9 additional Business Names available in full report.

General Information
Number of Employees: 178 (As of 12/31/2025)
Outstanding Shares: 39,179,277 (As of 3/3/2026)
Shareholders: 1,500
Stock Exchange: SWF
Fax Number: +41 447334740


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, March 24, 2026